Genetic drivers of human plasma metabolites that determine mortality in heart failure patients with reduced ejection fraction.

ABSTRACT:

Background

Heart failure with reduced ejection fraction (HFrEF) remains a significant public health issue, with the disease advancing despite neurohormonal antagonism. Energetic dysfunction is a likely contributor to residual disease progression, and we have previously reported a strong association of plasma metabolite profiles with survival among patients with HFrEF. However, the genetic and biologic mechanisms that underlie the metabolite-survival association in HFrEF were uncertain.

Methods and results

We performed genetic mapping of the key metabolite parameters, followed by mediation analyses of metabolites and genotypes on survival, and genetic pathway analyses. Patients with HFrEF (n = 1,003) in the Henry Ford Pharmacogenomic Registry (HFPGR; 500 self-reported

SUBMITTER: Revathi Venkateswaran V 

PROVIDER: S-EPMC11263106 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature